Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC

BSE3154.75-5.2 (-0.16 %)

PREV CLOSE ( ) 3159.95

OPEN PRICE ( ) 3180.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 1590

TODAY'S LOW / HIGH ( )3120.85 3217.10

52 WK LOW / HIGH ( )1924.3 3515.95

NSE3144.20-18.2 (-0.58 %)

PREV CLOSE( ) 3162.40

OPEN PRICE ( ) 3175.00

BID PRICE (QTY) 3144.20 (87)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 115563

TODAY'S LOW / HIGH( ) 3120.40 3220.00

52 WK LOW / HIGH ( )1921 3515.7

Select year

(Rs.in Million)

Particulars

Mar 2025

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Profit Before Tax

12551.87

9598.03

8414.94

24756.48

7230.95

Adjustment

-684.09

-451.30

-400.03

-16364.84

-256.41

Changes In working Capital

1848.28

610.21

-457.46

1198.72

457.46

Cash Flow after changes in Working Capital

13716.05

9756.95

7557.46

9590.36

7432.00

Cash Flow from Operating Activities

12898.97

5820.16

4842.25

8107.48

5779.11

Cash Flow from Investing Activities

-458.01

87.12

8078.51

-4055.08

4180.26

Cash Flow from Financing Activities

-7694.20

-5614.97

-15433.23

-5242.42

-6955.60

Net Cash Inflow / Outflow

4746.77

292.30

-2512.46

-1190.02

3003.78

Opening Cash & Cash Equivalents

641.71

349.41

2861.87

4051.89

1048.12

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

5388.48

641.71

349.41

2861.87

4051.89